Codexis, Inc. (NASDAQ:CDXS) Stake Lifted by Northern Trust Corp

Northern Trust Corp increased its stake in Codexis, Inc. (NASDAQ:CDXS) by 16.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 688,189 shares of the biotechnology company’s stock after acquiring an additional 98,256 shares during the period. Northern Trust Corp owned approximately 0.85% of Codexis worth $3,283,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in CDXS. CenterBook Partners LP bought a new position in shares of Codexis in the fourth quarter valued at approximately $4,688,000. Tallon Kerry Patrick acquired a new stake in Codexis during the fourth quarter valued at approximately $2,018,000. Vanguard Group Inc. lifted its stake in Codexis by 7.5% during the fourth quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company’s stock valued at $21,292,000 after purchasing an additional 311,082 shares during the last quarter. Telemark Asset Management LLC lifted its stake in Codexis by 11.3% during the fourth quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company’s stock valued at $14,310,000 after purchasing an additional 303,589 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Codexis by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company’s stock valued at $8,853,000 after purchasing an additional 211,475 shares during the last quarter. 78.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Codexis to a “sell” rating in a research note on Friday, May 16th.

Codexis Stock Down 2.4%

CDXS stock opened at $2.40 on Friday. Codexis, Inc. has a 12 month low of $1.90 and a 12 month high of $6.08. The firm has a market cap of $198.83 million, a PE ratio of -2.76 and a beta of 2.56. The firm has a 50 day simple moving average of $2.40 and a 200 day simple moving average of $3.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15.

Codexis (NASDAQ:CDXS) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The business had revenue of $7.54 million for the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. Equities research analysts forecast that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.